➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
AstraZeneca
Colorcon

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RABAVERT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for RABAVERT

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02374814 Immunogenicity of Rabies Vaccine for Pre Exposure Active, not recruiting Walter Reed Army Institute of Research (WRAIR) Phase 4 2015-03-01 The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
NCT02374814 Immunogenicity of Rabies Vaccine for Pre Exposure Active, not recruiting State University of New York - Upstate Medical University Phase 4 2015-03-01 The purpose of this study is to compare the effectiveness of a two dose versus a three dose schedule and intramuscular versus intradermal injection for pre-exposure prophylaxis.
NCT02564471 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting Kansas State University Phase 4 2016-04-01 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting Walter Reed Army Institute of Research (WRAIR) Phase 4 2016-04-01 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Recruiting State University of New York - Upstate Medical University Phase 4 2016-04-01 This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT04062669 A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults Not yet recruiting GlaxoSmithKline Phase 1 2019-08-15 The purpose of this first time-in-human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of three different dose levels of an experimental rabies glycoprotein G (RG) vaccine (RG-SAM [CNE] vaccine), made using a new technology, when administered intramuscularly (IM) on a 0, 2, 6-month schedule to healthy adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RABAVERT

Condition Name

Condition Name for RABAVERT
Intervention Trials
Rabies 2
Virus Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for RABAVERT
Intervention Trials
Rabies 3
Virus Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for RABAVERT

Trials by Country

Trials by Country for RABAVERT
Location Trials
United States 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for RABAVERT
Location Trials
New York 2
Maryland 1
Kansas 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for RABAVERT

Clinical Trial Phase

Clinical Trial Phase for RABAVERT
Clinical Trial Phase Trials
Phase 4 2
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for RABAVERT
Clinical Trial Phase Trials
Recruiting 1
Active, not recruiting 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for RABAVERT

Sponsor Name

Sponsor Name for RABAVERT
Sponsor Trials
State University of New York - Upstate Medical University 2
Walter Reed Army Institute of Research (WRAIR) 2
GlaxoSmithKline 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for RABAVERT
Sponsor Trials
Other 3
U.S. Fed 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Moodys
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.